Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

NCT04740307 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab/Quavonlimab
DRUG: Lenvatinib
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC